The new anesthesia diet plan: keeping perioperative carbs in check.
D. Coursin,R. Prielipp
DOI: https://doi.org/10.1213/01.ANE.0000130388.70236.29
2004-08-01
Abstract:A nesthesiologists are increasingly expected to achieve new standards of perioperative glucose control (1–8). Although attention is often focused on the nearly 30,000 children, adolescents, and young adults newly diagnosed each year with Type 1 diabetes mellitus (DM) (attributed to pancreatic islet cell failure and an absolute deficiency of insulin that results in an obligate need for insulin), this incidence has not changed in more than 50 yr (9). By contrast, there is an epidemic of Type 2 DM, which manifests as a spectrum of glucose dysregulation secondary to a combination of relative insulin deficiency, peripheral insulin resistance, and excessive hepatic gluconeogenesis (10,11). Type 2 DM is managed with diet, oral hypoglycemic drugs, and insulin preparations, alone or in combination (9,10). The number of newly diagnosed Type 2 diabetics is approaching 1 million cases annually, and this incidence has doubled in the past decade. Obesity, inactivity, excessive carbohydrate ingestion, and chronic inflammation all contribute to the increasing prevalence, and although it is most often diagnosed in the elderly, Type 2 DM is increasing in younger individuals as well (9–11). Despite, or perhaps because of, these epidemic proportions, one third of Type 2 diabetics still go undiagnosed. Thus, anesthesia preoperative assessment may need to include routine fasting glucose screening or measurement of glycosylated hemoglobin (hemoglobin A1c) in inactive, obese, high-risk patients. Earlier diagnosis and proper treatment may delay or prevent the onset of renal, vascular, ophthalmic, and cardiac disease (4,12). The DM alarm is ringing loudly, with reports by Narayan et al. (13) suggesting that a male child born in 2000 has approximately a 30% chance and a female child a 40% likelihood of developing DM during his or her lifetime. DM is currently the number 6 cause of death in the United States and is frequently present in patients who have cardiovascular disease and stroke, the first and third leading causes of death in this country, respectively (14,15). Cardiac disease is especially common in diabetics and is the most common cause of death in this population (12). Not surprisingly, therefore, 28% of patients undergoing coronary artery surgery are diabetic (7). Diabetic patients have more frequent, more prolonged, and more expensive hospitalizations that result in more morbidity and mortality than nondiabetics (9,16). Diabetics also require more frequent surgical interventions and are more often admitted to an intensive care unit (ICU). Furthermore, it is common for even nondiabetic surgical and ICU patients to develop acute hyperglycemia mediated by the release of proinflammatory cytokines (such as tumor necrosis factorand interleukin-6) and increasing concentrations of catecholamines, growth hormone, glucagon, and glucocorticoids (17). What can and should be done to manage hyperglycemia during hospitalization? The work by Carvalho et al. (18) in this issue of the journal highlights the rediscovery of a clinically superior method for insulin and glucose administration to maintain endocrine homeostasis throughout a particularly challenging period: during and immediately after cardiopulmonary bypass (19). Previous efforts to tightly control blood glucose in this population through the traditional approach of monitoring blood sugar and then responding with escalating doses of regular insulin have simply proven unsuccessful and may predispose patients to delayed and significant hypoglycemia (20). It appears that Carvalho et al. (18) have identified a better way. Although the methodology for administering insulin and glucose may be debated, the clinical end-point is well accepted. Convincing evidence suggests that clinical outcome is improved in cardiac surgery patients treated to maintain blood glucose 110 mg/dL ( 7 mmol/dL) (2,7,21). Van den Berghe et al. (21) achieved postoperative euglycemia with aggressive Accepted for publication February 4, 2004. Address correspondence and reprint requests to Douglas B. Coursin, MD, Department of Anesthesiology, B6/319 UW CSC, Madison, WI 53792-3272. Address e-mail to dcoursin@facstaff.wisc.edu.